|
Abstract:
|
Designing a Single-Use Biopharmaceutical Process, 2p. |
|
Abstract:
|
Evaluating the Rewards vs. the Risks of Automation, 5p. |
|
Abstract:
|
Expansion in Cell Culture Facility Offerings, 3p. |
|
Article:
|
Analysis of Residual Impurities in Continuous Manufacturing |
|
Article:
|
Best Practices in the QC Micro Laboratory |
|
Article:
|
Can Nanotechnology Deliver Big Drug Benefits? |
|
Article:
|
Can Policy Keep Pace with Science and Discoveries?
The promise of new therapies is tempered by the need for affordability, safety, and ethics. |
|
Article:
|
Can Vaccine Development Be Safely Accelerated? |
|
Article:
|
Contamination Control for Cell Therapy |
|
Article:
|
Design Considerations for a Commercial Cell and Gene Therapy Facility |
|
Article:
|
Flexible Facilities for Viral Vector Manufacturing |
|
Article:
|
Managing Biologic Equipment Cleaning |
|
Article:
|
More Predictable Post-Approval Change Policy on Horizon, 2p. |
|
Article:
|
Moving From Compliance to Quality |
|
Article:
|
Prepping Fill/Finish Systems to Ensure Quality Output |
|
Article:
|
Seeing Success with Single-Use Solutions |
|
Article:
|
Taking Stock of Biologic Fill/Finish Best Practices |
|
Article:
|
Taking Therapeutic Antibodies to the Next Level |
|
Article:
|
The Case for Stainless Steel |
|
Article:
|
The Case for Stainless Steel |
|
Article:
|
The Case for Stainless Steel |
|
Article:
|
What’s New in Downstream Processing |